Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
MedPlus Health Services has informed the stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for the Drug License of one of its stores located at Gollapudi One Center in Andhra Pradesh. The order was issued by the Assistant Director, District Sales Licensing Authority, Drugs Control Administration, Vijayawada, on December 31, 2025. The license has been suspended for seven days under Rule 65 of the Drugs and Cosmetics Act, 1940, and the associated Rules. The company has estimated a potential revenue loss of approximately ₹2.10 lakhs from this action. The order pertains to a single store and is a routine regulatory compliance matter.
The financial impact is negligible at around ₹2.10 lakhs for a single store's seven-day suspension, and is unlikely to have any meaningful effect on the company's overall operations or stock price. This appears to be a routine regulatory action with no material bearing on MedPlus's business.